Analyst Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Cytokinetics and keeping the price target at $120.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Joseph Pantginis has given his Buy rating due to a combination of factors that highlight the promising potential of Cytokinetics’ aficamten. The recent presentations at the 2025 Hypertrophic Cardiomyopathy Society and American Heart Association Scientific Sessions showcased aficamten’s significant benefits, particularly in improving patient-reported outcomes. These improvements in quality of life metrics, as demonstrated in trials like SEQUOIA-HCM and FOREST-HCM, underscore the drug’s effectiveness.
Furthermore, the data presented included robust biomarker analyses and responder studies, which further validate aficamten’s therapeutic impact. The anticipation of U.S. approval next month and the upcoming ACACIA-HCM readout, which could establish aficamten as a first-in-class treatment, also contribute to Pantginis’s optimistic outlook. These factors collectively support the potential for strong commercial uptake, justifying the Buy rating.